Reddy, Sunil A.

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 1,258

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy

Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 396

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 192

Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT

Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., & Mittra, E. (2019) · Clinical Nuclear Medicine

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 101